Summary Vascular endothelial growth factor (VEGF) expression and mutations of cancer-related genes increase with cancer progression. This correlation suggests the hypothesis that oncogenes and tumour suppressors regulate VEGF, and a significant correlation between p53 alteration and increased VEGF expression in human lung cancer was reported recently. To further examine this hypothesis, we analysed VEGF protein expression and mutations in p53 and K-ras in 27 non-small-cell lung cancers (NSCLC): 16 squamous cell, six adenocarcinomas, one large cell, two carcinoids and two undifferentiated tumours. VEGF was expressed in 50% of the squamous cell carcinomas (SCC) and carcinoids but none of the others. p53 mutations occurred in 14 tumours (52%), and K-ras mutations were found in two adenocarcinomas and one SCC; there was no correlation between the mutations and VEGF expression. As nitric oxide also regulates angiogenesis, we examined NOS expression in NSCLC. The Ca2+-dependent NOS activity, which indicates NOS1 and NOS3 expression, was significantly reduced in lung carcinomas compared with adjacent non-tumour tissue (P < 0.004). Although the Ca2+-independent NOS activity, which indicates NOS2 expression, was low or undetectable in non-tumour tissues and most carcinomas, significant activity occurred in three SCC. In summary, our data do not show a direct regulation of VEGF by p53 in NSCLC. Finally, we did not find the up-regulation of NOS isoforms during NSCLC progression that has been suggested for gynaecological and breast cancers.
Tumours cannot exceed 1-2 mm3 volume without developing new blood vessels (Folkman, 1990) . Therefore, solid tumours must produce angiogenic factors, such as vascular endothelial growth factor (VEGF), at an early point in development (Hanahan and Folkman, 1996) . VEGF expression is critical in tumour models (Kim et al, 1993; Millauer et al, 1994) . VEGF overexpression occurs in human cancers of the lung (Mattem et al, 1995) , colon (Brown et al, 1993 ) and brain , and has been found to correlate with nuclear accumulation of p53 in human lung and colon cancer (Fontanini et al, 1997a; Kang et al, 1997) and poor prognosis in NSCLC (Mattern et al, 1995; Fontanini et al, 1997b ). VEGF expression is induced by hypoxia (Shweiki et al, 1992; Forsythe et al, 1996) , and a mutationally activated ras oncogene (Rak et al, 1995; Larcher et al, 1996; Mazure et al, 1996) or p53 (Kieser et al, 1994) acts synergistically with hypoxia to induce VEGF expression. In contrast, wild-type p53 down-regulates VEGF promoter activity (Mukhopadhyay et al, 1995) and upregulates the expression of the antiangiogenic factor thrombospondin-1 (Dameron et al, 1994) . These observations suggest that oncogenes and tumour-suppressor genes regulate angiogenesis. However, p53 alterations did not correlate with VEGF expression in brain cancers and, in a recent report, wild-type p53 did not repress hypoxia-induced transcription of VEGF (Agani et al, 1997) .
Hypoxia stimulates both VEGF and NOS2 expression, the latter in collaboration with cytokines (Melillo et al, 1995) . Nitric oxide mediates tumour vascularization and growth (Maeda et al, 1994; Jenkins et al, 1995; Thomsen et al, 1997) ; tumour blood flow (Tozer et al, 1997) and VEGF-stimulated proliferation of coronary endothelial cells depend on NOS activity (Ziche et al, 1997) . Combating tumour angiogenesis (Harris, 1997 ) is a promising therapeutic strategy that may target expression of VEGF, NOS and other components of the angiogenesis pathway. Hence, we characterized the expression of VEGF and NOS in 27 NSCLC in relation to p53 and K-ras mutations. Although there are no correlations between those factors in NSCLC, we did find a statistically significant reduction in Ca2+-dependent NOS activity (NOS1 and -3) in tumour vs non-tumour tissue and a marked NOS2 expression in three squamous cell carcinomas.
MATERIALS AND METHODS Materials A1-monomethyl-L-arginine (L-NMA), flavin adenine dinucleotide (FAD) and (6R,S)-5,6,7,8-tetrahydro-L-biopterin (BH4) were purchased from Calbiochem (San Diego, CA, USA); the Dowex AG 50W-X8 resin, 200-400 mesh, sodium form, from Bio-Rad (Richmond, CA, USA), and the BCA protein reagent from Pierce (Rockford, IL, USA); rabbit polyclonal anti-NOS2 antibodies were either purchased from Transduction Laboratories (Lexington, KY, USA) or kindly provided by Merck (Rahway, NJ, USA); the rabbit polyclonal anti-VEGF (A-20) antibody was purchased from Santa 
Assay of NOS activity
The conversion of L-arginine to L-citrulline was measured using a modification of a described method (Salter et al, 1991 Sequence analysis of the p53 and K-ras genes Paraffin-embedded tumour samples were dewaxed and microdissected from 50-gm sections. Genomic DNA was isolated by SDS/proteinase K treatment (final concentration, 1% SDS and 0.5 mg ml-' of proteinase K) at 50°C for 24-48 h, followed by phenol-chloroform extraction, ethanol precipitation and resuspension in 50 ,ul of sterile water. The most common mutated p53 coding sequence from exons 4-10 was amplified (58°C, 1 min; 72°C, 0.5 min; 94°C, 1 min) and sequenced with the T7 sequenase kit (Amersham) using amplification and sequencing conditions as described by Lehman et al (1991) . For purification before sequencing, the polymerase chain reaction (PCR) products were loaded on a 4% agarose gel (3:1 NuSieve) and separated from leftover primers by electrophoresis at 50 V for 2 h. K-ras was amplified and sequenced as described (Lehman et al, 1991) with the following two primer pairs, consisting of an external primer pair for first-round PCR and an internal primer pair for a second-round PCR and sequencing: external primer pair, 5'-primer GTACTGGTGGAGTATlllGAT, 3'-primer GAGACTGGTAAAAGTACTCA; internal primer pair, 5'-primer ACATGTTCTAATATAGTCAC, 3'-primer GACCACGTCCTGGTAAGAAA.
Statistical analysis
Comparisons between two characteristics were carried out using the Mann-Whitney U rank-sum test. Relationships were considered statistically significant when P < 0.05.
RESULTS

VEGF expression
Positive staining for VEGF was obtained in 8 out of 16 SCC (50%). VEGF was expressed in the cytosol of tumour epithelial cells ( Figure 1A-D) and was focally distributed in most cases.
VEGF expression was also observed in one atypical carcinoid tumour (Figure 1 D) but not in six adenocarcinomas, one carcinoid, one large-cell carcinoma or two undifferentiated NSCLCs (Table   1 ). The specificity of VEGF immunohistochemistry (IHC) was verified by Western blot analysis with the detection of expected VEGF protein bands at 24-28 kDa ( Figure 5 ) in extracts of NSCLCs, which showed intensive VEGF immunostaining. VEGF protein bands were not detected in NSCLCs, which were negative for VEGF by IHC (data not shown).
p53 and K-ras mutations, and the relation to VEGF p53 mutations were detected in 14 cases (52%). One SCC had a 2 l-bp deletion mutation in exon 4, while all other mutations were missense mutations in exons 5-8 (Table 1) . G > T transversions (5 out of 14, 36%) were the most common mutations. p53 gene mutations and nuclear p53 protein accumulation correlated strongly (P < 0.01). Two adenocarcinomas and one SCC carried K-ras mutations at codon 12 (Table 1) . Out of eight SCC that expressed VEGF, five had aberrant p53 function indicated by nuclear p53
protein accumulation or mutation analysis, while one other tumour carried a K-ras mutation ( Figure 2 Ca2+-dependent NOS activity in human lung cancer. The activity was determined as the L-NMA-sensitive conversion of arginine to citrulline. Ca2+-dependent NOS activity is significantly decreased in lung carcinoma compared with the activity in the surrounding normal tissue (both n = 27) Ca2+-independent NOS activity in lung. NOS activity was measured as the L-NMA-sensitive conversion of arginine to citrulline, + 0.5 mM EGTA. Although Ca2+-independent NOS activity was mainly low or undetectable in lung and did not differ significantly between carcinomas (CA) and normal tissue (N), a marked activity was present in three carcinomas eight SCC without detectable VEGF expression carried a p53 mutation as shown by mutation analysis (Table 1) . Hence, the frequency of p53 inactivation, judged by nuclear protein accumulation in tumour cells or the presence of a mutation, was lower in SCC with VEGF expression (63%) than in SCC without detectable VEGF expression (88%). The combined frequency of p53/K-ras alterations was 75% in VEGF-positive SCC and 88% in VEGFnegative SCC. Thus, there was no association between VEGF expression in SCC and an apparent loss of p53 function and/or activation of K-ras.
NOS activity and NOS2 expression in lung tissues
Ca2+-dependent NOS activity, suggesting the presence of the neuronal (NOS 1) and/or endothelial (NOS3) isoforms, was counterstain. Both carcinomas contained high Ca2+-independent NOS activity significantly reduced in tumour tissue compared with normal lung tissue (both n = 27, P < 0.004) (Figure 2 ). Although Ca2+-independent NOS activity was mainly low or undetectable in lung tissues and did not differ significantly between carcinomas and normal tissue (P = 0.15), high activities were found in three SCC (Figure 3 ). Since Ca2+-independent NOS activity denotes NOS2 expression, we used IHC to determine the distribution of NOS2 protein.
In the three tumours with high Ca2+-independent NOS activity, NOS2 was detected in tumour-infiltrating monocytes ( Figure 4A ). NOS2 was also present in the tumour endothelium of two tumours and in the tumour epithelium of one SCC ( Figure 4B ). The expression of NOS2 was focal in all cases. We buttressed these observations with the detection of the specific 130-kDa NOS2 protein band by Western blot analysis. Using the protein extract of carcinoma no. 1 (see Table 1 ), which was positive for both NOS2 and VEGF by IHC, we obtained the 130-kDa band of NOS2 ( Figure  5 ). The protein expression data support the observation of NOS2 activity within these tumours.
DISCUSSION
The expression of VEGF correlates temporally with the onset of mutations in cancer-related genes, and mutations in both ras (Rak Figure 5 Detection of NOS2 and VEGF protein by Western blot analysis. Protein extracts from SCC no. 1 (T) and the surrounding normal tissue (N) were analysed. Protein bands were obtained at 130 kDa for NOS2 (A) and a double band at 26-28 kDa for VEGF (B). In agreement with the IHC analysis, only the carcinoma contains detectable amounts of NOS2 and VEGF protein. For NOS2, 300 ,ug of protein extract were separated on a 7% polyacrylamide gel. For VEGF, 5 1ig of a polyclonal anti-VEGF antibody were mixed with 1 mg of protein extract. The complex was precipitated with protein-A sepharose, heated at 950C, and the supernatants, containing the total immunoprecipitated VEGF, were loaded on a 13% gel. After transfer to an Immobilon-P membrane, the Western blots were probed with either a polyclonal anti-human NOS2 antibody or with a polyclonal anti-VEGF antibody et Larcher et al, 1996; Mazure et al, 1996) and p53 (Kieser et al, 1994) act synergistically with hypoxia to induce VEGF expression. Furthermore, wild-type p53 regulates NOS2 promoter activity (Forrester et al, 1996) , and NOS expression has been associated with the progression of gynecological and breast cancers (Thomsen et al, 1994; Thomsen et al, 1995) . These observations suggest that oncogenes and tumour suppressors may modulate angiogenesis, possibly by regulating VEGF and NOS expression.
We investigated VEGF and NOS expression in 27 NSCLC. VEGF was expressed in 50% of the SCC and carcinoids, as demonstrated by IHC analysis. We did not detect VEGF protein in six adenocarcinomas, although it has been reported (Mattern et al, 1995) . We found that Ca2+-dependent NOS activity, consistent with neuronal and/or endothelial NOS, was significantly reduced in tumours compared with adjacent normal lung tissue. The presence of both isoforms has been demonstrated in nerve elements and large-vessel endothelial cells in normal human lung (Kobzik et al, 1993) . Reduced tumour vascularity may have caused the decrease in Ca2+-dependent NOS activity. Three SCC had focally intense NOS2 expression in tumour-infiltrating monocytes, and endothelial cells lining larger vessels were labelled in two tumours. Only one SSC had a small focus of tumour cells that stained for NOS2. The expression of NOS2 in three SCCs may have been caused by circulating cytokines (Forstermann and Kleinert, 1995) , perhaps in synergy with hypoxia (Melillo et al, 1995) . The regions of NOS2 expression did not overlap with areas of VEGF expression, which suggests that NOS2 and VEGF are induced by different stimuli. Constitutive NOS2 expression was shown recently in the mucosa of non-inflamed human bronchus (Guo et al, 1995) . We could not detect the Ca2+-independent activity of NOS2 in most extracts from normal lungs nor did we find evidence by immunohistochemical staining. Our results indicate that constitutive NOS2 expression is not abundant in normal human lung and may be restricted to bronchial mucosa in the proximal airways that were not examined in our study.
p53 mutations occur in 56% of NSCLC (Greenblatt et al, 1994) , and one-third of adenocarcinomas have K-ras mutations (Rodenhuis et al, 1992) . Mutations in both genes, specifically the excess of guanine to thymine transversions observed in lung cancers, have been linked to tobacco smoking (Takahashi et al, 1991; Rodenhuis et al, 1992) . We found p53 mutations in 52% of our lung cancers and K-ras mutations in 33% of the adenocarcinomas. The predominance of guanine to thymine transversions that account for 36% of p53 mutations and all of the three K-ras mutations is consistent with the high rate of smoking in our series. We did not find a correlation between VEGF expression, K-ras mutation or p53 alteration (i.e. either mutation or protein overexpression). The rates of K-ras mutation and p53 alteration were 75% in VEGF-positive SCCs and 88% in VEGF-negative SCCs. The low rates of both mutation and VEGF expression among non-SCC tumours precluded inferences of association. These results contrast with a recent report that found a statistically significant association between p53 and VEGF by IHC (Fontanini et al, 1997a) . The most notable difference between the series was the 95% rate of VEGF expression reported by Fontanini and coworkers vs the 50% in SCCs in our cohort vs 59% in SCC in a third report (Mattern et al, 1995) . The discrepancy might be explained by methodological differences, including the use of different anti-VEGF antibodies and by cohort differences; the Fontanini series had more metastatic tumours than ours. The polyclonal anti-VEGF antibody (A-20) we used to detect VEGF in NSCLC was recently published in two colon cancer series (Takahashi et al, 1995; Kang et al, 1997) . We also tested another polyclonal anti-VEGF antibody that was applied recently to analyse NSCLCs (Fontanini et al, 1997a) . Our experiments suggested that the A-20 antibody is more specific for immunochemistry. Finally, we observed that detection of VEGF protein with the A-20 antibody correlates with VEGF mRNA expression in human carcinoma cells in cell culture (data not shown).
In summary, we found that up-regulation of NOS isoforms is not associated with progression of NSCLC, as has been suggested for gynaecological and breast cancers (Thomsen et al, 1994 . VEGF was expressed in 50% of SCC, however we found no correlation with p53 and K-ras alterations. Although oncogene and tumour-suppressor regulation of angiogenesis is an attractive model for carcinogenesis, these data do not link p53 and K-ras mutations with increased expression of VEGF or NOS isoforms in NSCLC. ABBREVIATIONS VEGF, vascular endothelial growth factor; NO, nitric oxide; NOS, nitric oxide synthase; SCC, squamous cell carcinoma; NSCLC, non-small-cell lung cancer; IHC, immunohistochemistry; L-NMA, L-NG-monomethyl-L-arginine; EGTA, ethylene glycol bis-(f-aminoethyl ether)-N,N'-tetraacetic acid
